Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 haploidentical stem cell transplant conditioning regimens for high-risk hematologic malignancies
ACTRN12622001232729Phase 2Recruiting
- Sponsor
- St Vincent's Hospital
- Start
- Sep 2023
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 2
01
Overview
Phase 2, open-label trial of fludarabine, treosulfan, cyclophosphamide, mycophenolate mofetil, tacrolimus and 1 more in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML) and 4 more (4 arms), sponsored by St Vincent's Hospital. Primary endpoints: Transplant-related mortality in RIC TBI 400 cGy regimen, Transplant-related mortality in MAC regimens and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
fludarabinetreosulfancyclophosphamidemycophenolate mofetiltacrolimus
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on ACTRN12622001232729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001232729.